Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03071913 · ClinicalTrials.gov registry record
Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery
A clinical trial of Metastatic Malignant Neoplasm in the Brain and Recurrent Brain Neoplasm, sponsored by Mayo Clinic.
- Completed
- Registry status
- 54
- Enrollment target
- 1
- Study location
NCT03071913: Completed study of Metastatic Malignant Neoplasm in the Brain and Recurrent Brain Neoplasm, sponsored by Mayo Clinic.
NCT03071913 is a study of Metastatic Malignant Neoplasm in the Brain and Recurrent Brain Neoplasm that has completed, run by Mayo Clinic. The registered enrollment target is 54 participants, below the 87-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03071913, a study of Metastatic Malignant Neoplasm in the Brain and Recurrent Brain Neoplasm, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may help them to determine which types of drugs may be best for treating brain tumors.
Primary Outcome
The ratio of cefazolin and levetiracetam (or lorazepam) and gadolinium in blood taken every 20-30 minutes during surgery will be correlated with the tissue samples. Inter- and intra-subject variability over all patients will be estimated, within specific imaging features between patients, and within open biopsy specimens.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2023-01-12 |
What the finished NCT03071913 record still lists
NCT03071913 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 87-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (38% lower).
The record links to 4 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT03071913 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03071913 about?
NCT03071913 is a clinical study titled "Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery". This pilot research trial studies blood brain barrier differences in patients with brain tumors undergoing surgery. Studying samples of tissue and blood from patients with brain tumors in the laboratory may help doctors to understand how well drugs get into different parts of a brain tumor. This may...
What is the current status of trial NCT03071913?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2017-09-20. Estimated completion is 2023-01-12.
What conditions does trial NCT03071913 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm, Central Nervous System Neoplasm, Localized Brain Neoplasm.
What interventions are being tested in trial NCT03071913?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT03071913?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03071913 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03071913's enrollment target sits among peer trials
54 22nd of 43 higher than 22 of 43 other Metastatic Malignant Neoplasm in the Brain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Malignant Neoplasm in the Brain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
RECRUITING
-
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
RECRUITING · NA
-
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
RECRUITING · NA
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI